Aspira Pathlab & Diagnostics Ltd
ASPIRAAspira Pathlab & Diagnostics Ltd
ASPIRA
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -310.33 | 5.53 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.49 | 6.67 | 0.52% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Aspira Pathlab & Diagnostics Limited is an India-based company engaged in diagnostic centre and laboratories related business. The Company operates Pathology labs and diagnostics centers across India.
Peers
Compare with peersMax Healthcare Institute Ltd
Apollo Hospitals Enterprise Ltd
Fortis Healthcare Ltd
Global Health Ltd
Narayana Hrudayalaya Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.32 | 1.07 | 4.58 | 7.89 | 8.71 | 15.41 | 19.63 | 14.78 | 13.62 | 17.63 | ||||||||||
Raw Materials | 0.00 | 0.14 | 1.30 | 2.26 | 1.99 | 2.63 | 3.14 | 2.50 | 2.62 | 16.32 | ||||||||||
| Power & Fuel Cost | 0.00 | 0.12 | 0.42 | 0.49 | 0.32 | 0.13 | 0.21 | 0.24 | 0.26 | |||||||||||
| Employee Cost | 0.08 | 1.61 | 3.42 | 4.47 | 4.95 | 4.03 | 5.02 | 5.59 | 6.20 | |||||||||||
| Selling & Administrative Expenses | 0.12 | 1.39 | 2.61 | 2.64 | 1.92 | 2.16 | 2.94 | 2.59 | 2.59 | |||||||||||
| Operating & Other expenses | 0.03 | 0.07 | 0.48 | 1.03 | 1.07 | 2.74 | 1.86 | 1.95 | 2.72 | |||||||||||
EBITDA | 0.09 | -2.26 | -3.65 | -3.00 | -1.54 | 3.72 | 6.46 | 1.91 | -0.77 | 1.31 | ||||||||||
| Depreciation/Amortization | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.51 | ||||||||||
| PBIT | 0.09 | -2.46 | -4.77 | -4.23 | -3.20 | 2.28 | 4.82 | 0.32 | -2.31 | -0.20 | ||||||||||
| Interest & Other Items | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | — | ||||||||||
| PBT | 0.04 | -2.72 | -5.57 | -5.19 | -4.21 | 1.39 | 4.45 | -0.10 | -2.68 | -0.20 | ||||||||||
| Taxes & Other Items | 0.01 | 0.00 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | — | ||||||||||
| Net Income | 0.03 | -2.72 | -5.57 | -5.19 | -4.24 | 1.39 | 4.45 | -0.10 | -2.68 | -0.20 | ||||||||||
| EPS | 0.13 | -7.31 | -10.73 | -7.75 | -4.85 | 1.42 | 4.32 | -0.10 | -2.60 | -0.19 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Aspira Pathlab & Diagnostics Ltd | -23.16 | 5.53 | — |
| Max Healthcare Institute Ltd | 106.23 | 13.36 | 0.13% |
| Apollo Hospitals Enterprise Ltd | 116.19 | 14.26 | 0.22% |
| Fortis Healthcare Ltd | 84.74 | 5.93 | 0.15% |
Price Comparison
Compare ASPIRA with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
ASPIRA has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
Hmm, looks like data is unavailable here. Please come back after some timeNet profit of Aspira Pathlab & Diagnostics reported to Rs 0.99 crore in the quarter ended September 2024 as against net loss of Rs 0.71 crore during the previous quarter ended September 2023. Sales rose 86.14% to Rs 6.18 crore in the quarter ended September 2024 as against Rs 3.32 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales6.183.32 86 OPM %21.84-10.84 - PBDT1.35-0.32 LP PBT0.99-0.71 LP NP0.99-0.71 LP Powered by Capital Market - Live
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 12 November 2024Powered by Capital Market - Live
Aspira Pathlab & Diagnostics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net Loss of Aspira Pathlab & Diagnostics reported to Rs 0.02 crore in the quarter ended June 2024 as against net loss of Rs 0.72 crore during the previous quarter ended June 2023. Sales rose 78.46% to Rs 4.64 crore in the quarter ended June 2024 as against Rs 2.60 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales4.642.60 78 OPM %7.54-12.69 - PBDT0.36-0.33 LP PBT-0.02-0.72 97 NP-0.02-0.72 97 Powered by Capital Market - Live
Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Aspira Pathlabs shares rise amidst Q1 results; promoters mull increasing stake in co
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 11.54%, vs industry avg of 10.02%
Constant Market Share
Over the last 5 years, market share stayed at 0.02%